Skip to main content

Fulgent Genetics, Inc.

corporate_fare Company Profile

Fulgent Genetics, Inc.

FLGT·NASDAQ·Industrial Applications And Services·CIK 0001674930

Fulgent is a technology-based company operating a laboratory services business and a therapeutic development business. Its laboratory services business provides technical laboratory and testing services, along with professional interpretation of laboratory results by licensed physicians. The therapeutic development business focuses on creating product candidates for various cancers using a nanoencapsulation and targeted therapy platform. This platform aims to enhance the therapeutic window and pharmacokinetic profile of both new and existing cancer drugs. Founded in 2011, Fulgent offers and develops diagnostic and genetic tests and laboratory services. The company's laboratory services include comprehensive anatomic pathology testing, covering gastrointestinal, dermatopathology, urologic, breast, neuropathology, and hematopathology. These services are supported by CLIA-licensed laboratories in the United States. Fulgent has also invested in digital pathology using AI technology to digitize specimen slides. The company also provides precision diagnostics testing services, including next-generation sequencing (NGS) tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and other disease subtypes. Specialized oncology services are part of precision diagnostics, utilizing technologies such as flow cytometry, cytogenetic analysis, fluorescence in-situ (FISH), immunohistochemistry, molecular genetics, NGS, and consultations in hematopathology and surgical pathology. Additionally, Fulgent offers testing services and licensing to pharmaceutical or biotech companies, contract research organizations (CROs), or sponsored testing programs, referred to as BioPharma services.

Fulgent Genetics, Inc. (NASDAQ:FLGT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 17 items for FLGT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for FLGT spans 10-Q, 8-K, SCHEDULE 13D/A, DEFA14A.

Recent high-impact activity:

  • Fulgent 10-Q: Q3 Revenue $90.4M, Gross Margin 35%, Nine-Month Loss $67.5M
  • Fulgent Q3 Revenue $90.4M, GAAP Loss $(0.48)/Share; FY26 Loss Guidance $46-50M
  • Fulgent Genetics Posts 48-Cent Loss Per Share in Third Quarter
  • Fulgent Genetics Q2 Losses Deepen as Billing Woes Crush Margins; Cash Burn Accelerates
  • Fulgent Genetics Q2 Revenue Misses, Guidance Slashed as Gross Margin Halves

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$322.67M
Net Income
-$60.51M
Op. Cash Flow
-$101.64M
Free Cash Flow
-$124.21M
Gross Profit
$130.88M
Operating Income
-$91.1M
Cash & Equivalents
$50.19M
Debt / Equity
0.00×
Net Margin
-18.8%
Shares Outstanding
31.08M sh
Source: 10-K · filed 2026-02-27 · accession 0001193125-26-079169

Short Interest & Short Volume

7.81 days to cover

FINRA reported short interest of 2,017,619 shares in FLGT as of the October 30, 2026 settlement, a 5.4% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 49.0% of FLGT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,017,619 shares as of October 30, 2026
Change vs prior period▼ 5.4%
Days to cover7.81 at avg daily volume of 258,478
Daily short volume (FINRA facilities)49.0% of 90,614 shares on November 20, 2026
5-day average short volume53.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with F →
$24.12
52-week range · as of 2026-11-05 $13.46 – $31.04
Market cap
$673.89M
Volume
323K (0.9× avg)
3-mo avg 348.8K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FLGT - Latest Insights

FLGT
Nov 05, 2026, 4:09 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.66
Real-time Price: $24.12 info
Change: +$5.46 (+29%) info
Market Cap: $673.889M info
FLGT
Nov 05, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.66
Real-time Price: $24.12 info
Change: +$5.46 (+29%) info
Market Cap: $673.889M info
FLGT
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $18.66
Real-time Price: $24.12 info
Change: +$5.46 (+29%) info
Market Cap: $673.889M info
FLGT
Jul 30, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.80
Real-time Price: $24.12 info
Change: +$10.32 (+75%) info
Market Cap: $673.889M info
FLGT
Jul 30, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.80
Real-time Price: $24.12 info
Change: +$10.32 (+75%) info
Market Cap: $673.889M info
FLGT
Jun 01, 2026, 7:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $18.09
Real-time Price: $24.12 info
Change: +$6.03 (+33%) info
Market Cap: $673.889M info
FLGT
May 21, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $17.50
Real-time Price: $24.12 info
Change: +$6.62 (+38%) info
Market Cap: $673.889M info
FLGT
May 14, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.19
Real-time Price: $24.12 info
Change: +$7.93 (+49%) info
Market Cap: $673.889M info
FLGT
May 01, 2026, 7:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $13.80
Real-time Price: $24.12 info
Change: +$10.32 (+75%) info
Market Cap: $673.889M info
FLGT
Mar 31, 2026, 4:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $15.90
Real-time Price: $24.12 info
Change: +$8.22 (+52%) info
Market Cap: $673.889M info
FLGT
Mar 31, 2026, 4:13 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $15.90
Real-time Price: $24.12 info
Change: +$8.22 (+52%) info
Market Cap: $673.889M info
FLGT
Mar 17, 2026, 4:36 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.43
Real-time Price: $24.12 info
Change: +$8.69 (+56%) info
Market Cap: $673.889M info
FLGT
Mar 11, 2026, 5:24 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $14.21
Real-time Price: $24.12 info
Change: +$9.91 (+70%) info
Market Cap: $673.889M info
FLGT
Feb 27, 2026, 7:15 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $21.90
Real-time Price: $24.12 info
Change: +$2.22 (+10%) info
Market Cap: $673.889M info
FLGT
Feb 27, 2026, 7:13 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $23.51
Real-time Price: $24.12 info
Change: +$0.610 (+3%) info
Market Cap: $673.889M info
FLGT
Feb 27, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.51
Real-time Price: $24.12 info
Change: +$0.610 (+3%) info
Market Cap: $673.889M info
FLGT
Feb 27, 2026, 7:00 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $23.51
Real-time Price: $24.12 info
Change: +$0.610 (+3%) info
Market Cap: $673.889M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets